BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth

BTIG, an investment firm, has issued a positive outlook for ImmunityBio, Inc. (IBRX), highlighting expected strong sales growth for its product ANKTIVA in 2026, which could drive stock upside if projections materialize. However, this forecast is based on future estimates and may already be partially priced into the market, with potential risks from regulatory hurdles or broader biotech sector challenges. Overall, while it suggests potential revenue expansion, investors should remain cautious due to the long-term nature and external economic factors.